Vanguard Global Advisers
CTKB icon

Vanguard Global Advisers’s Cytek Biosciences CTKB Stock Holding History

Vanguard Global Advisers’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Hold
45,212
– – ﹤0.01% 2501
2026
Q1 		$198K Buy
+45,212
New +$213K ﹤0.01% 2444

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Global Advisers's CTKB Position: Q2 2026 in Review

Vanguard Global Advisers held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 45,212 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Vanguard Global Advisers first reported a position in CTKB in Q1 2026 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Vanguard Global Advisers held 45,212 shares of Cytek Biosciences worth $200K as of Q2 2026.
  • Vanguard Global Advisers left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2501 holding.
  • Vanguard Global Advisers first reported a position in Cytek Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.